Desloratadine in Patients With Ulcerative Colitis

Recruiting now · Phase 2

Conditions studied: Ulcerative Colitis (UC), Ulcerative Colitis

In brief

The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.

Key facts

Study ID

NCT07333716

Run by

Tanta University

People needed

44

Starts

2026-01-26

Expected to finish

2027-03-01

Last updated by the study team

2026-01-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Both male and female sex.
• patients with age ranged from 18 to 65.
• patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline.
• Patients treated with 5-aminosalisylic acid (mesalamine).

You may not qualify if…

• Patients with severe UC
• Significant liver or kidney function abnormalities
• Pregnant or lactating females
• Treatment with systemic or rectal steroids
• Treatment with immunosuppressant or biological therapies
• Known allergy to desloratadine or any ingredient in the formulation
• Patients with other inflammatory diseases
• Patients with history of colon cancer
• Patients with complete or partial colectomy

Where it is running

• Menofia university Hospitals — Shibīn al Kawm, Menofia, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.